
Geovax Labs (GOVX) Stock Forecast & Price Target
Geovax Labs (GOVX) Analyst Ratings
Bulls say
Geovax Labs is facing a more constrained near-term outlook due to limited catalysts and tightening capital resources. Despite progress in their ongoing clinical trials for their vaccines and immunotherapies, the company's liquidity remains a concern with only $3.1M in cash at the end of 2025. As a result, the analyst lowers their rating from Buy to Hold and removes their price target, citing the elevated risk of dilutive capital raises in the future. However, upcoming milestones in regulatory engagement and the initiation of new clinical trials may provide validation for the company's pipeline in the long term.
Bears say
Geovax Labs is shifting its focus towards their lead candidate GEO-MVA and a next-generation COVID-19 vaccine, supported by the recent completion of clinical supply manufacturing and regulatory alignment. While these developments may give the company a differentiated role in the market, their limited balance sheet poses a significant financing risk. Additionally, while Gedeptin shows potential, sustained investment is needed and further dilution is likely. Beyond GEO-MVA, the company also has multiple portfolio programs approaching value-inflection points, including Gedeptin in combination with an immune checkpoint inhibitor in head and neck cancer, and their unique AGE1 continuous avian cell-line manufacturing platform.
This aggregate rating is based on analysts' research of Geovax Labs and is not a guaranteed prediction by Public.com or investment advice.
Geovax Labs (GOVX) Analyst Forecast & Price Prediction
Start investing in Geovax Labs (GOVX)
Order type
Buy in
Order amount
Est. shares
0 shares